| http://www.w3.org/ns/prov#value | - And FDA does anticipate that products for this indication will be submitted and we need to know how to regulate and how to assist these products.The difficulty and the challenge here is that they are -- there is a lack of clear definitions, lack of clear entry criteria, lack of clear endpoints and a path forward for drug development.
|
